MP regimen

chemotherapy protocol consisting of above cpds; used in the treatment of advanced bladder cancer; do not confuse with MP protocol (melphalan & prednisone) nor with MP combination (melphalan & prednisolone)

Networked: 8 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Therapy Context: Research Results

Experts

1.	Bos, Gerard M J: 1 article (03/2016)
2.	Brouwer, Rolf E: 1 article (03/2016)
3.	Coenen, Juleon L L M: 1 article (03/2016)
4.	Deenik, Wendy: 1 article (03/2016)
5.	Durian, Marc F: 1 article (03/2016)
6.	Gruber, Astrid: 1 article (03/2016)
7.	Hansson, Markus: 1 article (03/2016)
8.	Haukås, Einar: 1 article (03/2016)
9.	Klein, Saskia K: 1 article (03/2016)
10.	Levin, Mark-David: 1 article (03/2016)

Related Diseases

1.	Multiple Myeloma 05/01/1987 - "HLBI-MP regimen is thus expected to be useful in the clinical management of patients with multiple myeloma." 05/01/1987 - "Six patients with multiple myeloma were treated with HLBI-MP regimen; HLBI 300 X 10(4)U/day daily, Melphalan 4 mg/day p.o. " 02/01/2004 - "To investigate whether combination chemotherapy with vincristine, cyclophosphamide, prednisolone, and melphalan (COP/ MP) with the addition of ranimustine (MCNU) (MCNU-COP/MP) is superior to the slightly modified COP/MP (mCOP/MP) regimen in multiple myeloma (MM), a multicenter randomized study was performed. " 03/01/1991 - "The efficacy of alternating vincristine, melphalan (M), cyclophosphamide, prednisone/vincristine, carmustine, doxorubicin, and prednisone (VMCP/VBAP) polychemotherapy was compared with the M and prednisone (MP) regimen as induction treatment in multiple myeloma (MM). " 06/01/1993 - "To determine whether combination chemotherapy with alternating cycles of vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) and vincristine, carmustine (BCNU), Adriamycin (doxorubicin; Farmitalia, Carlo-Erba Laboratories, Spain), and prednisone (VBAP) is better than the standard melphalan-prednisone (MP) regimen in multiple myeloma (MM). "
2.	Spinal Cord Injuries (Spinal Cord Injury) 12/01/2014 - "Although the results of American National Acute Spinal Cord Injury Study 2 and 3 trials led to the wide adoption of a high-dose MP regimen for ASCI patients,the reliabilities of their study methods and data were still questionable. " 11/01/2014 - "Although the results of NASCIS (National Acute Spinal Cord Injury Study) II and III trials led to the widespread adoption of a high-dose MP regimen for patients treated within 8 hours of injury, subsequent studies have called into question the validity of NASCIS conclusions. " 11/01/1998 - "A randomized double-blind clinical trial was conducted to compare neurological and functional recovery and morbidity and mortality rates 1 year after acute spinal cord injury in patients who had received a standard 24-hour methylprednisolone regimen (24MP) with those in whom an identical MP regimen had been delivered for 48 hours (48MP) or those who had received a 48-hour tirilazad mesylate (48TM) regimen. "
3.	Reinjuries 11/01/2014 - "Although the results of NASCIS (National Acute Spinal Cord Injury Study) II and III trials led to the widespread adoption of a high-dose MP regimen for patients treated within 8 hours of injury, subsequent studies have called into question the validity of NASCIS conclusions. "
4.	Disease Progression 03/03/2016 - "We randomly assigned 668 patients between nine 4-week cycles of MPT followed by thalidomide maintenance until disease progression or unacceptable toxicity (MPT-T) and the same MP regimen with thalidomide being replaced by lenalidomide (MPR-R). "

Related Drugs and Biologics

1.	Melphalan (Alkeran)
2.	Vincristine (Oncovin)
3.	Cyclophosphamide (Cytoxan)
4.	Prednisolone (Predate)
5.	ranimustine
6.	Prednisone (Sone)
7.	Doxorubicin (Adriamycin)
8.	Carmustine (FIVB)
9.	Thalidomide (Thalomid)
10.	Methylprednisolone

Related Therapies and Procedures

1.	Combination Drug Therapy (Combination Chemotherapy)